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Outcomes Associated with Brain Metastases in a Three-Arm
Phase III Trial of Gemcitabine-Containing Regimens Versus
Paclitaxel Plus Carboplatin for Advanced Non-small Cell
Lung Cancer
Martin J. Edelman, MD,* Chandra P. Belani, MD,† Mark A. Socinski, MD,‡ Rafat H. Ansari, MD,§
Coleman K. Obasaju, MD, PhD, Ruqin Chen, MS, Matthew J. Monberg, MS,
and Joseph Treat, MD; for the Alpha Oncology Research Network
Background: Brain metastases (BMs) are a common complication
of non-small cell lung cancer (NSCLC). Because of historical data
indicating a poor prognosis for patients with BM, few randomized
phase III studies of advanced NSCLC have included patients with
BM at presentation. Because the potential benefits of systemic
therapy in patients with BM are uncertain, we analyzed data from a
recent phase III study.
Methods: One thousand one hundred thirty-five chemonaïve pa-
tients with stage IIIB/IV NSCLC were randomized to receive
gemcitabine/carboplatin, gemcitabine/paclitaxel, or paclitaxel/car-
boplatin. Stratification was based on presence or absence of BM,
stage, and baseline weight loss. Patients with BM were required to
be clinically stable after treatment with radiotherapy or surgery
before entry. Results were retrospectively analyzed by presence or
absence of BM at study entry.
Results: Rate of BM was 17.1% overall. The response rate was
28.9% for patients with BM (n  194) versus 29.1% without BM
(n  941). Time to progression was 4.3 months with BM and 4.6
months without BM (p  0.03). Median survival was 7.7 months
(95% confidence interval: 6.7–9.3) among patients with BM (n 
194) and 8.6 months (95% confidence interval: 7.9–9.5) for patients
without BM (n  941), p  0.09. Rates of hematologic adverse
events were not different among patients with and without BM.
Conclusions: There were no significant differences in response,
survival, or hematologic toxicity for patients with or without BM;
however, patients with BM had a small but significantly shorter time
to progression. Nonprogressing patients with treated BM are appro-
priate candidates for systemic therapy and entry into clinical trials.
Key Words: NSCLC, Phase III, Brain metastases, Nonplatinum
doublets.
(J Thorac Oncol. 2010;5: 110–116)
The estimated incidence of non-small cell lung cancer(NSCLC) in the United States is approximately 174,000
new cases each year.1 At the time of diagnosis, most patients
(80%) have locally advanced or metastatic disease, and the
5-year survival is less than 10% in this patient population.2,3
Chemotherapy has become standard treatment for patients with
advanced NSCLC, with platinum-based or nonplatinum dou-
blets producing a modest survival benefit and improvement in
quality of life compared with best supportive care alone.4–9
Brain metastasis (BM) is a common and serious com-
plication of NSCLC disease that is associated with significant
morbidity and poor survival.10 Estimates of BM among pa-
tients with NSCLC during the course of disease range from
30 to 50%, and lung cancer represents the most common
malignancy of the central nervous system.11–13 Analyses of
patients with lung cancer from the 1970s to 1980s indicated
that the incidence of BM among newly diagnosed patients
was approximately 10%.14,15
During that era, median survival associated with BM in
advanced or metastatic NSCLC was 3 months.16–19 Be-
cause of the poor prognosis, patients with BM have often
been treated with palliative measures such as steroids and
whole brain radiation therapy (WBRT).20,21 As a result of
poor prognosis and a concern that chemotherapy may have a
limited ability to cross the blood-brain barrier, few random-
ized phase III studies of advanced or metastatic NSCLC have
included patients with BM.22 However, the past 30 years have
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witnessed major technological advances in the ability to
diagnose asymptomatic BM. The routine adoption of com-
puted tomography and magnetic resonance imaging (partic-
ularly with contrast enhancement) at diagnosis have markedly
increased the ability to detect disease.23 In addition to im-
proved detection, there is considerable evidence that these
patients experience an improved overall prognosis.24,25 There
is also growing recognition that metastases of the central
nervous system are responsive to chemotherapy26,27; conse-
quently, it is important to reexamine the actual prognosis of
these patients and their suitability for routine entry onto
clinical trials.
Patients with stable BM were included in the phase III
trial described in the current report comparing a reference
regimen of paclitaxel/carboplatin to either gemcitabine/car-
boplatin or gemcitabine/paclitaxel. The overall clinical re-
sults have been reported previously.28 The current analysis
focuses on patient outcomes from the trial stratified by
presence or absence of BM.
PATIENTS AND METHODS
Patient Selection/Study Design
Detailed information with respect to patient selection
and study design of this trial is included in a separate
publication.29 Briefly, patients with a histologically con-
firmed diagnosis of stage IIIB (with pleural or pericardial
effusion), stage IV, or recurrent NSCLC were enrolled in this
study.30 Stage IV patients with BM were eligible provided
that, in the opinion of the site investigator, the BM were
clinically stable after treatment with surgery or WBRT.
Mixed tumors were categorized by the predominant cell
type unless small-cell anaplastic elements were present in
which case the patient was ineligible. All patients were
required to be 18 years of age and have measurable or
evaluable disease (according to Eastern Cooperative Oncol-
ogy Group solid tumor criteria); an Eastern Cooperative
Oncology Group performance status of 0 or 1; and adequate
bone marrow reserve (neutrophils 1500/mm3, platelets
100,000/mm3), adequate hepatic function (aspartate
transaminase5 times institutional upper limit of normal and
serum bilirubin 1.5 mg/dl times institutional ULN), and
adequate renal function (creatinine clearance 40 ml/min or
serum creatinine 1.5 mg/dl).
Patients who met all eligibility criteria were randomly
allocated to receive one of the following three treatment
regimens: arm A: gemcitabine 1000 mg/m2 infused over 30
minutes on days 1 and 8 plus carboplatin area under the curve
5.5 over 15 to 30 minutes on day 1; arm B: gemcitabine 1000
mg/m2 infused over 30 minutes on days 1 and 8 plus pacli-
taxel 200 mg/m2 infused over 3 hours on day 1; or arm C:
paclitaxel 225 mg/m2 infused over 3 hours on day 1 plus
carboplatin area under the curve 6.0 15 to 30 minutes on
day 1. Treatment cycles for all three treatment arms were
repeated every 21 days for six cycles or until unacceptable
toxicity or disease progression. Appropriate antiemetic and
supportive measures were used. At randomization, patients
were stratified by baseline weight loss, stage of disease, and
presence or absence of BM. Patients who developed BM as
the only evidence of progressive disease were able to be
treated with whole brain radiation and corticosteroids for BM
and remained on study. Chemotherapy was resumed 2 weeks
after the completion of brain irradiation. However, if the
patient failed to meet entry criteria after radiation therapy, the
patient was removed from the study.
This study was reviewed and approved by an ethical
review board at each participating institution, and it was
conducted in accordance with the precepts established by the
Declaration of Helsinki. Patients who were eligible for par-
ticipation provided written informed consent consistent with
all applicable governing regulations before undergoing any
study procedure or receiving any study drug.
Statistical Analysis
The sample size for this study was 1134 patients. The
large number of patients accrued in this study allowed for
statistical analyses of outcomes by specific patient subgroups.
Overall survival (OS), response rates (RRs), time to progres-
sion (TTP), and safety results were stratified by presence or
absence of BM. Survival and TTP were assessed using the
intention-to-treat population and calculated from the date of
randomization to the date of death or documented progres-
sion. The Kaplan-Meier product-limit method was used to
construct survival and TTP curves and calculate unadjusted
TABLE 1. Rate of Brain Metastases by Patient Subgroup
Characteristic
No. of
Patients in
Subgroup
Rate of Brain
Metastases in
Subgroup
(%)
p for
Comparison
within
Subgroup
All patients 1135 17.1 —
Age (yr)
70 797 21.3 0.0001
70 338 7.1
Gender
Male 688 15.7 0.12
Female 447 19.2
Ethnicity
White 972 16.7 0.75
African-American 138 18.8
Hispanic 9 22.2
Histology
Adenocarcinoma 537 19.0 0.001
Adenosquamous 23 17.4
Large cell 45 13.3
Squamous 202 6.9
Bronchioloalveolar 18 5.6
Performance status
0 427 12.9 0.008
1 699 19.7
2 4 0.0
Weight loss, n (%)
5 710 18.3 0.16
5 425 15.2
Disease stage IV or
recurrent disease
1019 19.0 —
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medians.31 TTP was defined as the time from randomiza-
tion to the first date of disease progression. For patients
who did not have documented disease progression and did
not receive any other antitumor therapy, TTP was censored
at the date of death or date of last visit. TTP was also
censored for patients who received other antitumor therapy
before disease progression. Response Evaluation Criteria
in Solid Tumors was used for response evaluation.32 RRs
were calculated by summing the number of patients with
complete responses and partial responses, and clinical
benefit rates were calculated by summing the number of
patients with complete responses, partial responses, and
stable disease. Safety was assessed by calculating the
percentage of patients experiencing grade 3 or 4 toxicities
using National Cancer Institute common toxicity criteria
version 2.0.33 All tests were two sided.34
To further compare outcomes by ethnicity and test for
potential treatment-by-BM interaction, Cox proportional haz-
ard models35 and a logistic regression model were created.
The reported multivariate models were cofactor adjusted for
weight loss, sex, performance status, ethnicity, and disease
stage and included main effects terms for treatment and BM
status. The treatment-by-metastases status interaction was
tested separately by adjusting for those factors.
RESULTS
Patient Characteristics
Between July 2000 and November 2005, 1135 pa-
tients were screened for eligibility/entry into this trial at
105 investigative sites in the United States. Of these, 194
(17.1%) had BM. Table 1 summarizes the rate of BM by
patient subgroup. The rate of BM was greater among
patients aged 70 years compared with 70 years (21.3%
versus 7.1%, p  0.0001) and was greater among patients
with nonsquamous histology compared with squamous
histology (19.3 versus 6.9%, p  0.0001).
Table 2 compares the baseline characteristics of pa-
tients with BM to patients without BM. The BM group
included a higher percentage of women (44.3%) compared
with the non-BM group (38.4%). The rate of BM was
uniform across treatment therapies.
Dose Administration
Study therapy was administered to 1077 patients
(94.9%) of the 1135 who were randomized. This included
183 of 194 patients (94.3%) with BM and 894 of 941 (95.0%)
without BM. Mean number of cycles administered was 3.7
(SD  1.9) for patients with BM and 3.8 (SD  1.9) for
patients without BM. The protocol-defined maximum of six
TABLE 2. Patient Characteristics by Brain Metastases Status
Characteristic
Brain Metastases
Present (N  194)
Brain Metastases
Absent (N  941)
Age
Median, yr (range) 60 (37–78) 65 (33–91)
70 yr, n (%) 170 (87.6) 627 (66.6)
70 yr, n (%) 24 (12.4) 314 (33.4)
Gender, n (%)
Male 108 (55.7) 580 (61.6)
Female 86 (44.3) 361 (38.4)
Ethnicity, n (%)
White 162 (83.5) 810 (86.1)
African American 26 (13.4) 112 (11.9)
Hispanic 2 (1.0) 7 (0.7)
Histology, n (%)
Adenocarcinoma 102 (52.6) 435 (46.2)
Adenosquamous 4 (2.1) 19 (2.0)
Large cell 6 (3.1) 39 (4.1)
Squamous 14 (7.2) 188 (20.0)
Bronchioloalveolar 1 (0.5) 17 (1.8)
Performance status, n (%)
0 55 (28.4) 372 (39.5)
1 138 (71.1) 561 (59.6)
2 0 (0.0) 4 (0.4)
Weight loss, n (%)
5 130 (67.0) 580 (61.6)
5 64 (33.0) 361 (38.4)
Disease stage, n (%)
IIIB with effusion 0 (0.0) 116 (12.3)
IV or recurrent disease 194 (100.0) 825 (87.7)
Assignment to treatment, n (%)
Gemcitabine-carboplatin 66 (34.0) 313 (33.3)
Gemcitabine-paclitaxel 64 (33.0) 313 (33.3)
Paclitaxel-carboplatin 64 (33.0) 315 (33.4)
N, number of patients; n, number in group.
TABLE 3. Main Efficacy Parameters
Variable
Brain Metastases
Present (N  194)
Brain Metastases
Absent (N  941)
Best overall response,
n (%)
Complete response 1 (0.5) 12 (1.3)
Partial response 55 (28.4) 262 (27.8)
Stable disease 56 (28.9) 328 (34.9)
Progressive disease 43 (22.2) 186 (19.8)
Unknown/not done 39 (20.1) 153 (16.3)
Response rate (CR  PR),
n (%) (95% CI)
56 (28.9) (22.6–35.8) 274 (29.1) (26.2–32.1)
Clinical benefit rate
(CR  PR  SD),
n (%) (95% CI)
112 (57.7) (50.4–64.8) 602 (64.0) (60.8–67.0)
Overall survival
Events, n (%) 182 (93.8) 852 (90.5)
Censored, n (%) 12 (6.2) 89 (9.5)
Median, mo (95% CI) 7.7 (6.7–9.3) 8.6 (7.9–9.5)
1 yr, % (95% CI) 30.6 (24.1–37.2) 36.1 (33.0–39.2)
2 yr, % (95% CI) 11.2 (6.7–15.8) 13.2 (10.9–15.5)
3 yr, % (95% CI) 4.2 (1.0–7.3) 6.6 (4.8–8.4)
Time to progression
Events, n (%) 183 (94.3) 871 (92.6)
Censored, n (%) 11 (5.7) 70 (7.4)
Median, mo, (95% CI) 4.3 (3.4–5.6) 4.6 (4.2–5.1)
CR, complete response; PR, partial response; N, number of patients; n, number in
group; CI, confidence interval.
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FIGURE 1. Kaplan-Meier estimates of overall survival (A) and time to disease progression (B) by brain metastases status of
present versus absent.
TABLE 4. Regression Analyses with Treatment by Brain Metastases Interaction Effect
Metastases Subgroup n
Response Rate, %
(95% CI)
Cofactor Adjusted OR
(95% CI) p for OR Treatment by Metastases Interaction p
Present
Gemcitabine/carboplatin 66 28.8 (18.3–41.3) 1.30 (0.59–2.85) 0.52 0.18 comparing gemcitabine/carboplatin
and paclitaxel/carboplatinGemcitabine/paclitaxel 64 34.4 (23.0–47.3) 1.68 (0.77–3.66) 0.19
Paclitaxel/carboplatin 64 23.4 (13.8–35.7) 1.0 (reference) Reference
Absent
Gemcitabine/carboplatin 313 24.6 (19.9–29.8) 0.72 (0.51–1.03) 0.07 0.26 comparing gemcitabine/paclitaxel and
paclitaxel/carboplatinGemcitabine/paclitaxel 313 31.6 (26.5–37.1) 1.01 (0.72–1.42) 0.94
Paclitaxel/carboplatin 315 31.1 (26.0–36.5) 1.0 (reference) Reference
Metastases Subgroup n
Median Survival, mo
(95% CI)
Cofactor Adjusted HR
(95% CI) p for HR Treatment by Metastases Interaction p
Present
Gemcitabine/carboplatin 66 7.6 (6.3–10.1) 0.97 (0.68–1.40) 0.89 0.79 comparing gemcitabine/carboplatin
and paclitaxel/carboplatinGemcitabine/paclitaxel 64 8.2 (4.6–10.5) 0.94 (0.65–1.36) 0.74
Paclitaxel/carboplatin 64 7.7 (6.1–10.2) 1.0 (reference) Reference
Absent
Gemcitabine/carboplatin 313 8.1 (7.1–9.3) 1.04 (0.88–1.22) 0.66 0.80 comparing gemcitabine/paclitaxel and
paclitaxel/carboplatinGemcitabine/paclitaxel 313 9.2 (7.7–10.2) 1.00 (0.85–1.18) 0.96
Paclitaxel/carboplatin 315 9.0 (7.8–10.3) 1.0 (reference) Reference
Metastases Subgroup n
Median TTP, mo
(95% CI)
Cofactor Adjusted HR
(95% CI) p for HR Treatment by Metastases Interaction p
Present
Gemcitabine/carboplatin 66 4.6 (3.2–6.3) 0.92 (0.64–1.33) 0.67 0.74 comparing gemcitabine/carboplatin
and paclitaxel/carboplatinGemcitabine/paclitaxel 64 3.9 (2.6–6.0) 1.06 (0.74–1.54) 0.74
Paclitaxel/carboplatin 64 5.0 (3.0–6.0) 1.0 (reference) Reference
Absent
Gemcitabine/carboplatin 313 4.3 (4.1–5.1) 1.0 (0.85–1.17) 0.98 0.57 comparing gemcitabine/paclitaxel and
paclitaxel/carboplatinGemcitabine/paclitaxel 313 4.8 (4.1–5.6) 0.97 (0.82–1.14) 0.71
Paclitaxel/carboplatin 315 4.6 (4.2–5.5) 1.0 (reference) Reference
Models were cofactor adjusted without interaction term.
HR, hazard ratio; n, number in group; OR, odds ratio; TTP, time to progression; CI, confidence interval.
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cycles was administered to 31.1% (n  57) of patients with
BM and 34.7% (n  310) of patients without BM. Relative
dose intensities (% of planned dose that was administered) of
gemcitabine (88.5% versus 87.6%), carboplatin (90.1% ver-
sus 91.0%), and paclitaxel (99.4% versus 98.8%) were sim-
ilar in patients with and without BM. The median time from
diagnosis to randomization was 58.4 days for the BM present
group and 41.0 days for the BM absent group.
The median time from diagnosis to the start of treat-
ment was 50.0 days for the BM present group and 29.0 days
for the BM absent group.
Efficacy
The primary results of this study demonstrated that all
three regimens produced similar efficacy in terms of OS, RR,
and TTP.28,29 Table 3 summarizes the main efficacy param-
eters in the trial by presence or absence of BM. Although
median survival was longer for patients without BM com-
pared with patients with BM (8.6 versus 7.7 months), differ-
ences in OS were not statistically significant (log-rank p 
0.09). At 3 years, 4.2% of patients with BM and 6.6% of
patients without BM were alive. RRs were 28.9% (95%
confidence intervals [CI]  22.6–35.8) for patients with BM
and 29.1% (95% CI  26.2–32.1) for patients without BM.
Median TTP measured from the date of randomization was
4.3 months for patients with BM (95% CI 3.4–5.6) and 4.6
months for patients without BM (95% CI  4.2–5.1). Dif-
ferences in TTP from the date of randomization were statis-
tically significant (log-rank p 0.03). However, median TTP
measured from the date of diagnosis was not statistically
significant between groups (6.5 months for the BM present
group [95% CI:5.1–7.3] and 5.8 months for the BM absent
group [95% CI  5.4–6.3]; p  0.58). Kaplan-Meier curves
from randomization for OS and TTP by BM status are shown
in Figure 1.
Table 4 summarizes a logistic regression model with
response as the outcome variable and two Cox regression
models with OS and TTP as the outcome variables, respec-
tively. Among patients with BM, RRs, OS, and TTP were
similar across treatment groups. In the BM group, median
survival ranged from 7.6 months (95% CI  6.3–10.1) in the
gemcitabine-carboplatin group to 8.2 months (95% CI 
4.6–10.5) in the gemcitabine-paclitaxel group. None of the
comparisons across treatment groups in any of the regression
models achieved statistical significance.
Toxicity
Chemotherapy safety is summarized for patients with
and without BM in Table 5. Rates of grade 3 or 4 hematologic
toxicities and rates of transfusions were similar between
patients with and without BM. Rates of grade 3 or 4 nonhe-
matologic toxicities were also similar by BM status. How-
ever, the rate of grade 3 or 4 nausea was greater among
patients with BM (10.9 versus 5.1%, p  0.006), as were
other grade 1 to 4 nonhematologic toxicities. These included
fatigue (78.7% versus 70.5%, p  0.02), anorexia (52.5%
TABLE 5. Toxicity According to Treatment Group (Safety Population)
Type of Toxicity
Brain Metastases Present
(N  183)
Brain Metastases Absent
(N  894) p-value
for Overall
ComparisonGrade 3 Grade 4 Grade 3 Grade 4
Hematologic events, n (%)
Neutropenia 32 (17.5) 23 (12.6) 146 (16.3) 136 (15.2) 0.73
Febrile neutropenia 6 (3.3) 0 (0.0) 22 (2.5) 7 (0.8) 1.0
Thromobocytopenia 37 (20.2) 11 (6.0) 197 (22.0) 246 (27.5) 0.79
Platelet transfusion 7 (3.8) 23 (2.6) 0.33
Anemia 27 (14.8) 0 (0.0) 90 (10.1) 3 (0.3) 0.09
Red blood cell transfusion 0 (0.0) 5 (0.6) 0.60
Transfusion 7 (3.8) 38 (4.3) 1.0
Nonhematologic events, n (%)
Arthralgia (Grade 3 or 4) 5 (2.7) 18 (2.0) 0.57
Alopecia (Grade 2) 85 (46.4) 343 (38.4) 0.17
Diarrhea (Grade 1 to Grade 4) 52 (28.4) 199 (22.3) 0.08
Nausea (Grade 3 or Grade 4) 20 (10.9) 46 (5.1) 0.006
Vomiting (Grade 1 to Grade 4) 64 (35.0) 249 (27.9) 0.06
Fatigue (Grade 1 to Grade 4) 144 (78.7) 630 (70.5) 0.02
Anorexia (Grade 1 to Grade 4) 96 (52.5) 329 (36.8) 0.001
Any nervous system disorder
(Grade 1 to Grade 4)
114 (62.3) 530 (59.3) 0.46
Cerebrovascular accident
(Grade 4)
0 (0.0) 3 (0.3) 1.0
Dizziness (Grade 1 to Grade 4) 26 (14.2) 65 (7.3) 0.003
Headache (Grade 1 to Grade 4) 24 (13.1) 50 (5.6) 0.001
Tremor (Grade 1 to Grade 4) 4 (2.2) 4 (0.4) 0.03
N, number of patients; n, number in group.
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versus 36.8%, p 0.001), dizziness (14.2% versus 7.3%, p
0.003), headache (13.1% versus 5.6%, p  0.001), and
tremor (2.2% versus 0.4%, p  0.03). No cerebrovascular
accidents occurred among patients with BM.
DISCUSSION
The brain is a common site of metastatic spread in
advanced NSCLC. It is likely that the incidence of BM is on
the rise with the increasing numbers of patients with adeno-
carcinoma histology.36 Consequently, it is important to de-
velop evidence-based guidelines for their overall manage-
ment. Historically, patients with BM have been excluded
from clinical trials because of poor prognosis. However, data
from the current report indicate that patients with or without
BM may experience similar outcomes when enrolled in
clinical trials of systemic therapy. OS was not significantly
different between patients with BM and without BM. Median
survival (8.6 months versus 7.7 months) and 1-year, 2-year,
and 3-year survival rates for patients with BM and without
BM mirrored each other, with a slight trend favoring patients
without BM. Patients without BM enjoyed a minimally su-
perior TTP compared with those without BM. Differences in
TTP between groups were possibly related to the longer time
from diagnosis to randomization and treatment for patients
with BM due to the administration of WBRT in patients with
BM. Three-year survival among patients with BM was 4.2%
(95% CI  1.0–7.3), which is encouraging. Regression
models showed that OS, RR, and TTP outcomes did not vary
by BM status across the three treatment groups in this trial,
suggesting that there may not be a preferred chemotherapeu-
tic regimen by BM status.
Reluctance to administer systemic chemotherapy to
patients with BM has been related to concerns of adequacy of
delivery across the blood-brain barrier. However, Ott et al.37
demonstrated that the blood-brain barrier in patients with BM
may in fact be permeable during treatment. Others have
demonstrated that it is possible to achieve therapeutic levels
of chemotherapy such as platinum agents within the spinal
fluid.38 Robinet et al.27 reported a trial in which patients (n 
167) received either early (at diagnosis) or delayed (after at
least two cycles of chemotherapy) WBRT. Patients received
chemotherapy (cisplatin/vinorelbine) concurrent with WBRT
in both arms. Chemotherapy alone produced an intracranial
RR of 27%, and there was no difference in median or
6-month survival between the two arms. Cotto et al. and
Minotti et al.39,40 reported 16% and 35% RR, respectively,
with 4 and 5.3 months of medium survival with evidence of
intracranial response. Lee et al.41 described an experience
with 30 patients treated at MD Anderson who were treated
with carboplatin and paclitaxel. They noted a higher RR in
the brain (33%) than in extracranial sites (23%). This re-
sponse was often accompanied by an increase in edema.
There were no significant differences by BM status
with respect to grade 3 or 4 hematologic toxicities. Patients
with BM were more likely to experience grade 1 to grade 4
fatigue, gastrointestinal symptoms, and nervous system dis-
orders when compared with patients without BM. Grades 1 to
4 nervous system disorders that had elevated rates among
patients with BM included dizziness, headache, and tremor.
One concern with respect to the incorporation of tar-
geted therapies such as vascular endothelial growth inhibitors
into the treatment of patients with BM is the risk of intracra-
nial hemorrhage or cerebrovascular events among patients
with BM. A recent analysis suggests that the rate of these
events is low and not different between patients with BM
compared with patients without BM.42 In this study, no
cerebrovascular accidents occurred among patients with BM,
compared with a 0.3% rate among patients without BM.
Accrual of patients with BM to trials of systemic
treatment for first-line advanced NSCLC has started to gain
acceptance. A review of 28 ongoing phase III trials registered
to the clinicaltrials.gov website indicates that as many as 70%
are open to enrolling patients with BM.43 The current analysis
suggests that this change in attitude is appropriate as the
outcomes among patients with BM seem to be similar to
those without BM.
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